The 22 Strobe Items and their sub-items

Items are labelled as XX# where XX represents the STROBE section [TA (title and abstract), IN (introduction), ME (methods), RE (results), DI (discussion)] and where # represents the STROBE item [1-22]. The text is extracted from the STROBE explanatory article 15 and the lowercase alphanumerical listing [(a), (b), (c), …] indicates the sub-items.

* **TA1** Title and abstract. (a) Indicate the study’s design with a commonly used term in the title or the abstract. (b) Provide in the abstract an informative and balanced summary of what was done and what was found.
* **IN2** Background/rationale. Explain the scientific background and rationale for the investigation being reported.
* **IN3** Objectives. State-specific objectives, including any prespecified hypotheses.(a) specific population, (b) exposures, (c) outcomes, (d) parameter to be estimated.
* **ME4** Methods. Study design. Present key elements of study design early in the paper.  
  Cohort: (a1) cohort, (a2) time period, (a3) exposure status;  
  Case-control: (b1) case description, (b2) control description, (b3) source, (b4) population;  
  Cross-sectional: (c1) population, (c2) timing.
* **ME5** Setting. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.
* **ME6** Participants.  
  Cohort: (a1) eligibility criteria, (a2) selection sources, (a3) selection method, (a4) methods of follow-up  
  Matched Cohort: (a5) For matched studies, give matching criteria and number of exposed and unexposed. Case-Controls: (b1) eligibility criteria, (b2) selection sources, (b3) selection method, (b4) rationale for the choice of cases and controls.  
  Matched Case-control study: (b5)For matched studies, give matching criteria and the number of controls per case  
  Cross-sectional (c1) eligibility criteria, (c2) selection sources, (c3) selection method
* **ME7** Variables. Clearly define all (a) outcomes, (b) exposures and predictors, (c) potential confounders and effect modifiers. Give (d) diagnostic criteria, if applicable.
* **ME8** Data sources/measurement. For each variable of interest, give (a) sources of data and (b) details of methods of assessment (measurement). Describe (c) comparability of assessment methods if there is more than one group.
* **ME9** Bias. Describe any efforts to address potential sources of bias.
* **ME10** Study size. Explain how the study size was arrived at.
* **ME11** Quantitative variables. Explain how quantitative variables were (a) handled in the analyses. If applicable, describe (b) which groupings were chosen and why.
* **ME12** Describe (a1) all statistical methods, including (a2) those used to control for confounding. (b) Describe any methods used to examine subgroups and interactions. (c) Explain how missing data were addressed.  
  Cohort: (d1) If applicable, explain how loss to follow-up was addressed.  
  Case-control: (d2) If applicable, explain how matching of cases and controls was addressed.  
  Cross-sectional: (d3) If applicable, describe analytical methods taking account of sampling strategy.  
  (e) Describe any sensitivity analyses.
* **RE13**(a) Report numbers of individuals at each stage of study—for example, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram.
* **RE14** Give characteristics of (a1) study participants (demographic, clinical, social) and information on (a2) exposures and (a3) potential confounders. (b) Indicate number of participants with missing data for each variable of interest.  
  Cohort: (c) Summarise follow-up time (eg, average and total amount)
* **RE15** Numbers  
  Cohort: (a) Report numbers of outcome events or summary measures over time.  
  Case-control: (b) Report numbers in each exposure category or summary measures of exposure.  
  Cross-sectional: (c) Report numbers of outcome events or summary measures
* **RE16**(a1) Give unadjusted estimates and, if applicable, (a2) confounder-adjusted estimates and (a3) their precision (eg, 95% confidence interval). (a4) Make clear which confounders were adjusted for and why they were included. (b) Report category boundaries when continuous variables were categorised. (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.
* **RE17** Other analyses. Report other analyses done—for example, analyses of subgroups and interactions and sensitivity analyses
* **DI18** Discussion Key results. Summarise key results with reference to study objectives.
* **DI19** Limitations. Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.
* **DI20** Interpretation. Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies and other relevant evidence.
* **DI21** Generalisability. Discuss the generalisability (external validity) of the study results.

**DI22** Funding. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.

Supplementary table 1. Variables and rate of reporting where applicable

Items are labelled as XX#\_y where XX represents the STROBE section [TA (title and abstract), IN (introduction), ME (methods), RE (results), DI (discussion)], where # represents the STROBE item [1-22], and where y is the lowercase alphanumerical listing [(a), (b), (c), …] indicating the sub-items defined in the section above.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Item** | **Reporting** | **Item** | **Reporting** | **Item** | **Reporting** |
| TA1 | 28.3% | ME6\_b3 | 56.9% | ME12\_e | 22.0% |
| TA1\_b | 91.0% | ME6\_b4 | 91.2% | RE13\_a | 47.5% |
| IN2 | 50.0% | ME6\_b5 | 26.3% | RE13\_b | 27.8% |
| IN3\_a | 94.2% | ME6\_c1 | 82.5% | RE13\_c | 17.5% |
| IN3\_b | 92.8% | ME6\_c2 | 38.6% | RE14\_a1 | 84.8% |
| IN3\_c | 99.1% | ME6\_c3 | 14.0% | RE14\_a2 | 91.0% |
| IN3\_d | 88.8% | ME7\_a | 90.6% | RE14\_a3 | 46.6% |
| ME4\_a1 | 50.0% | ME7\_b | 85.7% | RE14\_b | 27.4% |
| ME4\_a2 | 93.0% | ME7\_c | 37.2% | RE14\_c | 57.9% |
| ME4\_a3 | 93.0% | ME7\_d | 58.3% | RE15\_a | 96.5% |
| ME4\_b1 | 50.0% | ME8\_a | 94.2% | RE15\_b | 96.5% |
| ME4\_b2 | 94.7% | ME8\_b | 98.7% | RE15\_c | 98.2% |
| ME4\_b3 | 80.7% | ME8\_c | 31.4% | RE16\_a1 | 90.6% |
| ME4\_b4 | 96.5% | ME9 | 34.5% | RE16\_a2 | 18.8% |
| ME4\_c1 | 50.0% | ME10 | 42.2% | RE16\_a3 | 44.4% |
| ME4\_c2 | 78.9% | ME11\_a | 31.4% | RE16\_a4 | 52.9% |
| ME5 | 93.3% | ME11\_b | 31.4% | RE16\_b | 42.6% |
| ME6\_a1 | 14.0% | ME12\_a1 | 33.6% | RE16\_c | 0.9% |
| ME6\_a2 | 1.8% | ME12\_a2 | 50.7% | RE17 | 72.2% |
| ME6\_a3 | 10.5% | ME12\_b | 57.4% | DI18 | 99.6% |
| ME6\_a4 | 71.9% | ME12\_c | 27.4% | DI19 | 84.3% |
| ME6\_a5 | 8.8% | ME12\_d1 | 24.6% | DI20 | 94.6% |
| ME6\_b1 | 71.6% | ME12\_d2 | 15.8% | DI21 | 60.5% |
| ME6\_b2 | 97.2% | ME12\_d3 | 35.8% | DI22 | 75.8% |